Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.
After finishing at $13.46 in the prior trading day, Keros Therapeutics Inc (NASDAQ: KROS) closed at $13.55, up 0.67%. In other words, the price has increased by $0.67 from its previous closing price. On the day, 0.29 million shares were traded. KROS stock price reached its highest trading level at $13.775 during the session, while it also had its lowest trading level at $13.4.
Ratios:
Our goal is to gain a better understanding of KROS by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 0.76 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.71. For the most recent quarter (mrq), Quick Ratio is recorded 19.29 and its Current Ratio is at 19.29. In the meantime, Its Debt-to-Equity ratio is 0.03 whereas as Long-Term Debt/Eq ratio is at 0.02.
Wedbush Downgraded its Outperform to Neutral on January 17, 2025, while the target price for the stock was maintained at $15.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 09 ’25 when ADAR1 Capital Management, LLC bought 934,258 shares for $10.13 per share. The transaction valued at 9,464,512 led to the insider holds 4,392,737 shares of the business.
GORDON CARL L sold 250,000 shares of KROS for $11,002,500 on Aug 13 ’24. The Director now owns 119,522 shares after completing the transaction at $44.01 per share. On Aug 13 ’24, another insider, ORBIMED ADVISORS LLC, who serves as the Director of the company, sold 250,000 shares for $44.01 each. As a result, the insider received 11,002,500 and left with 119,522 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KROS now has a Market Capitalization of 550338688 and an Enterprise Value of -151789136. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.56 while its Price-to-Book (P/B) ratio in mrq is 0.75. Its current Enterprise Value per Revenue stands at -0.707 whereas that against EBITDA is 16.839.
Stock Price History:
The Beta on a monthly basis for KROS is 1.29, which has changed by -0.7016076 over the last 52 weeks, in comparison to a change of 0.092761636 over the same period for the S&P500. Over the past 52 weeks, KROS has reached a high of $72.37, while it has fallen to a 52-week low of $9.12. The 50-Day Moving Average of the stock is -2.13%, while the 200-Day Moving Average is calculated to be -54.15%.
Shares Statistics:
The stock has traded on average 971.66K shares per day over the past 3-months and 722190 shares per day over the last 10 days, according to various share statistics. A total of 40.56M shares are outstanding, with a floating share count of 33.61M. Insiders hold about 17.24% of the company’s shares, while institutions hold 89.34% stake in the company. Shares short for KROS as of 1748563200 were 5306156 with a Short Ratio of 5.46, compared to 1745971200 on 5266448. Therefore, it implies a Short% of Shares Outstanding of 5306156 and a Short% of Float of 20.47.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
